Anthem Biosciences Sustainability Profile
Anthem Biosciences, a leading biotechnology firm headquartered in India, has established itself as a key player in the life sciences industry since its inception in 2009. With a strong operational presence across various regions, the company focuses on providing innovative solutions in drug discovery, development, and manufacturing. Specialising in custom biologics, Anthem Biosciences offers a range of services, including monoclonal antibody development and protein expression systems. Their commitment to quality and efficiency sets them apart in a competitive market. Over the years, the company has achieved significant milestones, enhancing its reputation for excellence in biopharmaceutical services. Recognised for its cutting-edge technologies and robust client partnerships, Anthem Biosciences continues to drive advancements in the biotechnology sector, positioning itself as a trusted partner for pharmaceutical and biotech companies worldwide.
DitchCarbon Score
How does Anthem Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anthem Biosciences's score of 14 is lower than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Anthem Biosciences's reported carbon emissions
In 2024, Anthem Biosciences reported total carbon emissions of approximately 17,631,000 kg CO2e, with Scope 1 emissions accounting for about 13,561,000 kg CO2e and Scope 2 emissions at approximately 3,923,000 kg CO2e. This represents a significant increase from 2023, when total emissions were about 12,650,000 kg CO2e, with Scope 1 emissions of approximately 10,798,000 kg CO2e and Scope 2 emissions of around 2,355,000 kg CO2e. Anthem Biosciences has committed to reducing its carbon footprint, although specific reduction targets have not been disclosed. The company is actively engaged in initiatives to lower Scope 1 and Scope 2 emissions, including the use of cleaner fuels and renewable energy sources. However, there are currently no reported reductions in emissions from these initiatives. As of now, Anthem Biosciences has not committed to a net-zero target. The company is classified under the Pharmaceuticals, Biotechnology, and Life Sciences sector and operates from its headquarters in India. The emissions data is not cascaded from any parent organization, indicating that the figures are independently reported by Anthem Biosciences Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 10,798,000 | 00,000,000 |
| Scope 2 | 2,355,000 | 0,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Anthem Biosciences's Industry?
How Carbon Intensive is Anthem Biosciences's Location?
Anthem Biosciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Anthem Biosciences has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
